Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium

Maria E Goossens, Frank Buntinx, Steven Joniau, Koen Ackaert, Filip Ameye, Ignace Billiet, Johan Braeckman, Alex Breugelmans, Jochen Darras, Kurt Dilen, Lieven Goeman, Eliane Kellen, Bertrand Tombal, Siska Van Bruwaene, Ben Van Cleyenbreuge, Frank Van der Aa, Kris Vekemans, Hendrik Van Poppel, Maurice P Zeegers, Maria E Goossens, Frank Buntinx, Steven Joniau, Koen Ackaert, Filip Ameye, Ignace Billiet, Johan Braeckman, Alex Breugelmans, Jochen Darras, Kurt Dilen, Lieven Goeman, Eliane Kellen, Bertrand Tombal, Siska Van Bruwaene, Ben Van Cleyenbreuge, Frank Van der Aa, Kris Vekemans, Hendrik Van Poppel, Maurice P Zeegers

Abstract

Background: In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder cancer. This suggests that selenium may also be suitable for chemoprevention of recurrence.

Method: The SELEBLAT study opened in September 2009 and is still recruiting all patients with non-invasive transitional cell carcinoma of the bladder on TURB operation in 15 Belgian hospitals. Recruitment progress can be monitored live at http://www.seleblat.org. Patients are randomly assigned to selenium yeast (200 μg/day) supplementation for 3 years or matching placebo, in addition to standard care. The objective is to determine the effect of selenium on the recurrence of bladder cancer. Randomization is stratified by treatment centre. A computerized algorithm randomly assigns the patients to a treatment arm. All study personnel and participants are blinded to treatment assignment for the duration of the study.

Design: The SELEnium and BLAdder cancer Trial (SELEBLAT) is a phase III randomized, placebo-controlled, academic, double-blind superior trial.

Discussion: This is the first report on a selenium randomized trial in bladder cancer patients.

Trial registration: ClinicalTrials.gov identifier: NCT00729287.

References

    1. Cancer incidence in Belgium, 2008. Belgium Cancer registry, Brussels. 2011.
    1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer. 2010.
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–1330.
    1. Rayman MP, Infante HG, Sargent M. Food-chain selenium and human health: emphasis on intake. Br J Nutr. 2008;100:238–253.
    1. Whanger PD. Selenocompounds in plants and animals and their biological significance. J Am Coll Nutr. 2002;21:223–232.
    1. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther. 1998;79:179–192. doi: 10.1016/S0163-7258(98)00014-X.
    1. Sanmartin C, Plano D, Palop JA. Selenium compounds and apoptotic modulation: a new perspective in cancer therapy. Mini Rev Med Chem. 2008;8:1020–1031. doi: 10.2174/138955708785740625.
    1. Brozmanova J, Manikova D, Vlckova V, Chovanec M. Selenium: a double-edged sword for defense and offence in cancer. Arch Toxicol. 2010;84:919–938. doi: 10.1007/s00204-010-0595-8.
    1. Naithani R. Organoselenium compounds in cancer chemoprevention. Mini Rev Med Chem. 2008;8:657–668. doi: 10.2174/138955708784567368.
    1. Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol. 2006;13:1180–1184. doi: 10.1111/j.1442-2042.2006.01526.x.
    1. Torun M, Aldemir H, Yardim S. Serum selenium levels in various cancer types. Trace Elements and Electrocytes. 1995;12:186–190.
    1. Yalcin O, Karatas F, Erulas FA, Ozdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int. 2004;93:863–866. doi: 10.1111/j.1464-410X.2003.04729.x.
    1. Nomura A, Heilbrun LK, Morris JS, Stemmermann GN. Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data. J Natl Cancer Inst. 1987;79:103–108.
    1. Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res. 1989;49:6144–6148.
    1. Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA. Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2002;11:1292–1297.
    1. Michaud DS, Hartman TJ, Taylor PR, Pietinen P, Alfthan G, Virtamo J, Albanes D. No Association between toenail selenium levels and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1505–1506.
    1. Michaud DS, De Vivo I, Morris JS, Giovannucci E. Toenail selenium concentrations and bladder cancer risk in women and men. Br J Cancer. 2005;93:804–806. doi: 10.1038/sj.bjc.6602788.
    1. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers Maurice PA, Horneber M. Book Selenium for preventing cancer. City: John Wiley & Sons, Ltd; 2011. Selenium for preventing cancer. (Editor ed.^eds.)
    1. Rayman MP. The use of high-selenium yeast to raise selenium status: how does it measure up? Br J Nutr. 2004;92:557–573. doi: 10.1079/BJN20041251.
    1. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608–612. doi: 10.1046/j.1464-410X.2003.04167.x.
    1. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA. et al.Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA. 2009;301:39–51. doi: 10.1001/jama.2008.864.
    1. Goossens ME, Buntinx F, Zeegers MP. Re: Selenium and vitamin E: interesting biology and dashed hope. J Natl Cancer Inst. 2009;101:1363–1364. doi: 10.1093/jnci/djp272. author reply 1364.
    1. Brinkman M, Buntinx F, Muls E, Zeegers MP. Use of selenium in chemoprevention of bladder cancer. Lancet Oncol. 2006;7:766–774. doi: 10.1016/S1470-2045(06)70862-2.
    1. Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: Chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol. 2008;42:213–233.
    1. Altwein JE. [Primary prevention of bladder cancer. What's new?] Urologe A. 2007;46:616–621. doi: 10.1007/s00120-007-1348-z.
    1. Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol. 2006;176:1914–1920. doi: 10.1016/j.juro.2006.07.004.
    1. Amaral AF, Cantor KP, Silverman DT, Malats N. Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:2407–2415. doi: 10.1158/1055-9965.EPI-10-0544.
    1. Hatfield DL, Gladyshev VN. The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv. 2009;9:18–21. doi: 10.1124/mi.9.1.6.
    1. Larsen EH, Hansen M, Paulin H, Moesgaard S, Reid M, Rayman M. Speciation and bioavailability of selenium in yeast-based intervention agents used in cancer chemoprevention studies. J AOAC Int. 2004;87:225–232.
    1. Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol Nefrol. 2004;56:65–72.
    1. Navarro-Alarcon M, Cabrera-Vique C. Selenium in food and the human body: a review. Sci Total Environ. 2008;400:115–141. doi: 10.1016/j.scitotenv.2008.06.024.
    1. MacFarquhar JK, Broussard DL, Melstrom P, Hutchinson R, Wolkin A, Martin C, Burk RF, Dunn JR, Green AL, Hammond R. et al.Acute selenium toxicity associated with a dietary supplement. Arch Intern Med. 2010;170:256–261. doi: 10.1001/archinternmed.2009.495.
    1. Yang G, Zhou R, Yin S, Gu L, Yan B, Liu Y, Li X. Studies of safe maximal daily dietary selenium intake in a seleniferous area in China I. Selenium intake and tissue selenium levels of the inhabitants. J Trace Elem Electrolytes Health Dis. 1989;3:77–87.
    1. Food: and Nutrition Board - USA Institute of Medicine. Dietary References Intakes for Vitamin C, Vitamin E, Selenium and Carotenoids. Washington: National Academy Press; 2000.
    1. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56:247–256. doi: 10.1016/j.eururo.2009.04.038.
    1. Ashughyan VR, Marihart S, Djavan B. Chemopreventive trials in urologic cancer. Rev Urol. 2006;8:8–13.
    1. Lamm DL, Riggs DR, Shriver JS, Van Gilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151:21–26.
    1. Prout GR Jr, Barton BA. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group. J Cell Biochem Suppl. 1992;16I:148–152.
    1. Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL. et al.Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008;14:224–229. doi: 10.1158/1078-0432.CCR-07-0733.
    1. Studer UE, Jenzer S, Biedermann C, Chollet D, Kraft R, von Toggenburg H, Vonbank F. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol. 1995;28:284–290.
    1. Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol. 1995;27:110–116.
    1. Byar D, Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology. 1977;10:556–561. doi: 10.1016/0090-4295(77)90101-7.
    1. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006;176:500–504. doi: 10.1016/j.juro.2006.03.061.
    1. Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, Iguchi A, Kinukawa N. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J Urol. 2008;179:485–490.
    1. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol. 1995;27:104–109.
    1. Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, Hussain S, James N, Wallace DM, Cheng KK. The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU Int. 2009;105:784–788.
    1. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, Ahmann FR. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the 'Watchful Waiting' Study. Anticancer Drugs. 2003;14:595–600. doi: 10.1097/00001813-200309000-00004.
    1. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, Farinaro E, Clark LC, Reid ME. Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomized clinical trial. Am J Epidemiol. 2006;163:694–699. doi: 10.1093/aje/kwj097.
    1. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:217–223.
    1. Algotar AM, Stratton MS, Stratton SP, Hsu CH, Ahmann FR. No effect of selenium supplementation on serum glucose levels in men with prostate cancer. Am J Med. 2010;123:765–768. doi: 10.1016/j.amjmed.2010.02.018.
    1. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect. 2009;117:1409–1413.
    1. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 2011;117:1552–1556. doi: 10.1002/cncr.25641.
    1. Yang KC, Lee LT, Lee YS, Huang HY, Chen CY, Huang KC. Serum selenium concentration is associated with metabolic factors in the elderly: a cross-sectional study. Nutr Metab (Lond) 2010;7:38. doi: 10.1186/1743-7075-7-38.
    1. Stranges S, Navas-Acien A, Rayman MP, Guallar E. Selenium status and cardiometabolic health: state of the evidence. Nutr Metab Cardiovasc Dis. 2010;20:754–760. doi: 10.1016/j.numecd.2010.10.001.
    1. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and hypertension in the US Population. Circ Cardiovasc Qual Outcomes. 2009;2:369–376. doi: 10.1161/CIRCOUTCOMES.108.831552.
    1. Nawrot TS, Staessen JA, Roels HA, Den Hond E, Thijs L, Fagard RH, Dominiczak AF, Struijker-Boudier HA. Blood pressure and blood selenium: a cross-sectional and longitudinal population study. Eur Heart J. 2007;28:628–633.
    1. Rayman MP. Selenoproteins and human health: insights from epidemiological data. Biochim Biophys Acta. 2009;1790:1533–1540. doi: 10.1016/j.bbagen.2009.03.014.
    1. Yang GQ, Xia YM. Studies on human dietary requirements and safe range of dietary intakes of selenium in China and their application in the prevention of related endemic diseases. Biomed Environ Sci. 1995;8:187–201.
    1. Kellen E, Zeegers MP, Dirx M, Houterman S, Droste J, Lawrence G, Truyers C, Bruckers L, Molenberghs G, Joniau S, Buntinx F. Occurrence of both bladder and prostate cancer in five cancer registries in Belgium, The Netherlands and the United Kingdom. Eur J Cancer. 2007;43:1694–1700. doi: 10.1016/j.ejca.2007.04.011.
    1. Kellen E, Zeegers MP, Joniau S, Buntinx F. Examining the co-occurrence of bladder and prostate cancer: a worthwhile investigation? Future Oncol. 2007;3:515–519. doi: 10.2217/14796694.3.5.515.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa